Abstract:
We coated the candidate DNA vaccine containing SARS-CoV-2 nucleocapsid gene with liposome and detected its transfection efficiency in human cells 293T. SARS-CoV-2 N gene was cloned into eukaryotic expression vector pcDNA3.1
(+) and identified by DNA sequencing and mass spectrometry sequencing. Then, the pcDNA3.1
(+)-SARS-CoV-2 N gene nanoparticles coated by liposomes were prepared and detected by ultra-purification, nucleic acid electrophoresis, transmission electron microscope, and the liposome nanoparticles of 50−100 nm were formed by liposome coating. After quantification, the gene nanoparticles were transfected into 293T cells according to gradient concentration, and the transfection effects between liposome transfection and FUGENE ®HD transfection were compared. The results validated that the candidate recombinant liposome DNA vaccine formed stable nanoparticles with high efficiency expression in human cells 293T.